Moleculin Biotech, Inc.(MBRX)Earnings, Financials & Key RatiosMoleculin Biotech, Inc. (MBRX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's cash runway is rapidly depleting, evidenced by a contraction in cash from $23.6 million in 2023Q4 to $10.3 million in 2026Q1, which likely necessitates further dilutive capital raises.
Moleculin Biotech, Inc. (MBRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Moleculin Biotech, Inc. (MBRX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $2.48vs $1.69-46.7% | — |
| Q2 2026 | Mar 20, 2026 | $2.61vs $7.77+133.6% | — |
| Q4 2025 | Nov 13, 2025 | $3.25vs $5.00+35.0% | — |
| Q3 2025 | Aug 12, 2025 | $12.25vs $9.75-25.6% | — |
Recent stock market news and headlines for Moleculin Biotech, Inc. (MBRX)
HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor “What This Means” segment.
Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What This Means" segment.
Moleculin Biotech Inc. (NASDAQ:MBRX) stock is trading lower on Tuesday after the company shared preliminary efficacy data from the first 45 patients enrolled in Part A of its pivotal Phase 2/3 MIRACLE trial that did not reach statistical significance.
Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — reported on a full intent-to-treat (ITT) basis with no patient exclusions Composite complete remission (CRc) reached 50% and 57% in the respective Annamycin arms versus 29% for control Enrollment in the MIRACLE trial continues with more than two-thirds (67 of 90 subjects) of Part A target as Company advances toward optimal dose selection HOUSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the Company's pivotal Phase 2/3 MIRACLE trial, analyzed on a full intent-to-treat basis with no patient exclusions. Both Annamycin treatment arms demonstrated favorable efficacy trends compared with the control arm in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
Key metrics vs top competitors for Moleculin Biotech, Inc. (MBRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.32 | $95.69M | -0.08 | — | — | -319.85% | — | |
| $23.24 | $2.05B | -7.06 | 627.84% | -112.01% | -256.66% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $44.01 | $2.62B | -6.18 | 48.03% | -639.84% | -34.11% | — | |
| $4.75 | $192.85M | 3.89 | 36.55% | -19.55% | -3.39% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — |
Moleculin Biotech, Inc. (MBRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Moleculin Biotech, Inc. (MBRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 26, 2026·SEC
May 22, 2026·SEC
May 15, 2026·SEC
Mar 18, 2026·SEC
Get notified when MBRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Moleculin Biotech, Inc. (MBRX) stock FAQ — growth, dividends, profitability & financials explained
Moleculin Biotech, Inc. (MBRX) reported a net loss of $30.3M for fiscal year 2025.
Moleculin Biotech, Inc. (MBRX) has a return on equity (ROE) of -319.8%. Negative ROE indicates the company is unprofitable.
Moleculin Biotech, Inc. (MBRX) had negative free cash flow of $24.3M in fiscal year 2025, likely due to heavy capital investments.
